A Double-Blind,Randomized Study of Extended-Release Molindone for Impulsive Aggression in ADHD

Abstract

Objective: To evaluate efficacy and safety of SPN-810 (extended-release molindone) in a Phase-2b, randomized, double-blind, placebo-controlled, dose-ranging study of children (6–12 years) with ADHD and persistent impulsive aggression (IA). Method: After lead-in, children were randomized to (a) placebo (N = 31); (b) low-dose (N = 29, 12/18 mg/day); (c) medium-dose (N = 30, 24/36 mg/day); and (4) high-dose (N = 31, 36/54 mg/day) groups. Treatment included ~2.5-week titration, 3-week maintenance, and 1-week tapering/conversion, alongside existing monotherapy (stimulants/nonstimulants) and behavioral therapy. The primary endpoint was change in Retrospective-Modified Overt Aggression Scale (R-MOAS) score at end of study, with safety monitored. Results: A total of 95 (78.5%) children completed the study. Aggression (R-MOAS) improved with low and medium doses (low dose: p = .031; medium dose: p = .024; high dose: p = .740). The most common adverse events were headache (10.0%), sedation (8.9%), and increased appetite (7.8%). Conclusion: These results suggest SPN-810 may be effective in reducing residual IA behaviors in children with ADHD. Research is still needed to support the benefit–risk profile of SPN-810 in pediatric populations.

Keywords

molindone impulsive aggression stimulants attention-deficit/hyperactivity disorder maladaptive aggression

Get full access to this article

View all access options for this article.

References

Aldrimer

Ridefelt

Rodoo

Niklasson

Gustafsson

Hellberg

(2012). Reference intervals on the Abbot Architect for serum thyroid hormones, lipids and prolactin in healthy children in a population-based study. Scandinavian Journal of Clinical & Laboratory Investigation, 72(4), 326–332.

Aman

M. G.

Bukstein

O. G.

Gadow

K. D.

Arnold

L. E.

Molina

B. S.

McNamara

N. K.

. . . Findling

R. L.

(2014). What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder? Journal of the American Academy of Child & Adolescent Psychiatry, 53(1), 47–60 e41.

American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed., text rev.).

Barnes

T. R.

(1989). A rating scale for drug-induced akathisia. British Journal of Psychiatry, 154, 672–676.

Barratt

E. S.

Stanford

M. S.

Dowdy

Liebman

M. J.

Kent

T. A.

(1999). Impulsive and premeditated aggression: A factor analysis of self-reported acts. Psychiatry Research, 86(2), 163–173.

Bidzan

Pachalska

(2012). Aggressive and impulsive behavior in Alzheimer’s disease and progression of dementia. Medical Science Monitor, 18(3), CR182–CR189.

Biederman

Newcorn

Sprich

(1991). Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. American Journal of Psychiatry, 148(5), 564–577.

Blader

J. C.

Pliszka

S. R.

Jensen

P. S.

Schooler

N. R.

Kafantaris

(2010). Stimulant-responsive and stimulant-refractory aggressive behavior among children with ADHD. Pediatrics, 126(4), e796–e806.

Blader

J. C.

Schooler

N. R.

Jensen

P. S.

Pliszka

S. R.

Kafantaris

(2009). Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy. American Journal of Psychiatry, 166(12), 1392–1401.

10.

Busner

Targum

S. D.

(2007). The Clinical Global Impressions scale: Applying a research tool in clinical practice. Psychiatry, 4(7), 28–37.

11.

Campbell

Fish

Shapiro

Floyd

Jr. (1971). Study of molindone in disturbed preschool children. Current Therapeutic Research, Clinical and Experimental, 13(1), 28–33.

12.

Centers for Disease Control and Prevention. (2000a). 2 to 20 years: Boys stature-for-age and weight-for-age percentiles. https://www.cdc.gov/growthcharts/data/set1clinical/cj41cs021c.pdf

13.

Centers for Disease Control and Prevention. (2000b). 2 to 20 years: Girls stature-for-age and weight-for-age percentiles. https://www.cdc.gov/growthcharts/data/set1clinical/cj41c022.pdf

14.

Ceresoli-Borroni

Liranso

Brittain

S. T.

Connor

D. F.

Evans

C. J.

Findling

R. L.

. . . Nasser

(2019). Application of the impulsive aggression diary in adolescents with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 29(8), 599–607.

15.

Ceresoli-Borroni

Liranso

Brittain

S. T.

Connor

D. F.

Evans

C. J.

Findling

R. L.

. . . Schwabe

(2019). A novel assessment tool for impulsive aggression in children with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 29(8), 592–598.

16.

Collett

B. R.

Ohan

J. L.

Myers

K. M.

(2003). Ten-year review of rating scales. VI: Scales assessing externalizing behaviors. Journal of the American Academy of Child & Adolescent Psychiatry, 42(10), 1143–1170.

17.

Connor

D. F.

(2016). On the challenge of maladaptive and impulsive aggression in the clinical treatment setting. Journal of Child and Adolescent Psychopharmacology, 26(1), 2–3.

18.

Connor

D. F.

Glatt

S. J.

Lopez

I. D.

Jackson

Melloni

R. H.

Jr. (2002). Psychopharmacology and aggression. I: A meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. Journal of the American Academy of Child & Adolescent Psychiatry, 41(3), 253–261.

19.

Connor

D. F.

McLaughlin

T. J.

(2006). Aggression and diagnosis in psychiatrically referred children. Child Psychiatry & Human Development, 37(1), 1–14.

20.

Connor

D. F.

Newcorn

J. H.

Saylor

K. E.

Amann

B. H.

Scahill

Robb

A. S.

. . . Buitelaar

J. K.

(2019). Maladaptive aggression: With a focus on impulsive aggression in children and adolescents. Journal of Child and Adolescent Psychopharmacology, 29(8), 576–591.

21.

Cunningham

C. E.

(2006). COPE: Large-group, community-based, family-centered parent training. In Barkley

R. A.

(Ed.), Attention-deficit hyperactivity disorder: A handbook for diagnosis and treatment (pp. 480–498). Guilford Press.

22.

Divac

Prostran

Jakovcevski

Cerovac

(2014). Second-generation antipsychotics and extrapyramidal adverse effects. BioMed Research International, 2014, Article 656370.

23.

Dunlop

B. W.

Gray

Rapaport

M. H.

(2017). Transdiagnostic Clinical Global Impression scoring for routine clinical settings. Behavioral Sciences, 7(3), E40.

24.

Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. (2011). Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Summary report. Pediatrics, 128(Suppl. 5). S213–S256.

25.

Fossum

Handegard

B. H.

Martinussen

Morch

W. T.

(2008). Psychosocial interventions for disruptive and aggressive behaviour in children and adolescents: A meta-analysis. European Child & Adolescent Psychiatry, 17(7), 438–451.

26.

Fung

L. K.

Mahajan

Nozzolillo

Bernal

Krasner

. . . Hardan

A. Y.

(2016). Pharmacologic treatment of severe irritability and problem behaviors in autism: A systematic review and meta-analysis. Pediatrics, 137(Suppl. 2), S124–S135.

27.

Goodman

Faraone

Adler

Dirks

Hamdani

Weisler

(2010). Interpreting ADHD rating scale scores: Linking ADHD rating scale scores and CGI levels in two randomized controlled trials of lisdexamfetamine dimesylate in ADHD. Prim Psychiatry, 17(3), 44–52.

28.

Good Therapy.Org. (2010). Moban (molindone). https://www.goodtherapy.org/drugs/moban-molindone.html

29.

Greenhill

L. L.

Barmack

J. E.

Spalten

Anderson

Halpern

(1981). Molindone hydrochloride in the treatment of aggressive, hospitalized children [proceedings]. Psychopharmacology Bulletin, 17(1), 125–127.

30.

Greenhill

L. L.

Solomon

Pleak

Ambrosini

(1985). Molindone hydrochloride treatment of hospitalized children with conduct disorder. Journal of Clinical Psychiatry, 46(8, Pt. 2), 20–25.

31.

Guemes

Rahman

S. A.

Hussain

(2016). What is a normal blood glucose? Archives of Disease in Childhood, 101(6), 569–574.

32.

Gurnani

Ivanov

Newcorn

J. H.

(2016). Pharmacotherapy of aggression in child and adolescent psychiatric disorders. Journal of Child and Adolescent Psychopharmacology, 26(1), 65–73.

33.

Guy

(1976). ECDEU Assessment Manual for Psychopharmacology. National Institute of Mental Health, US Dept of Health, Education, and Welfare.

34.

James

L. M.

Strom

T. Q.

Leskela

(2014). Risk-taking behaviors and impulsivity among veterans with and without PTSD and mild TBI. Military Medicine, 179(4), 357–363.

35.

Jensen

P. S.

Youngstrom

E. A.

Steiner

Findling

R. L.

Meyer

R. E.

Malone

R. P.

. . . Vitiello

(2007). Consensus report on impulsive aggression as a symptom across diagnostic categories in child psychiatry: Implications for medication studies. Journal of the American Academy of Child & Adolescent Psychiatry, 46(3), 309–322.

36.

Kaufman

Birmaher

Brent

Rao

Flynn

Moreci

. . . Ryan

(1997). Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial reliability and validity data. Journal of the American Academy of Child & Adolescent Psychiatry, 36(7), 980–988.

37.

Knapp

Chait

Pappadopulos

Crystal

Jensen

P. S.

& T-MAY Steering Group. (2012). Treatment of Maladaptive Aggression in Youth: CERT guidelines I. Engagement, assessment, and management. Pediatrics, 129(6), e1562–e1576.

38.

Kose

Steinberg

J. L.

Moeller

F. G.

Gowin

J. L.

Zuniga

Kamdar

Z. N.

. . . Lane

S. D.

(2015). Neural correlates of impulsive aggressive behavior in subjects with a history of alcohol dependence. Behavioral Neuroscience, 129(2), 183–196.

39.

Krause

Zhu

Huhn

Schneider-Thoma

Bighelli

Chaimani

Leucht

(2018). Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysis. European Neuropsychopharmacology, 28(6), 659–674.

40.

Krishna

Gopalakrishnan

Goel

(2017). Toxicity assessment of molindone hydrochloride, a dopamine D2/D5 receptor antagonist in juvenile and adult rats. Toxicology Mechanisms and Methods, 27(5), 352–362.

41.

Loy

J. H.

Merry

S. N.

Hetrick

S. E.

Stasiak

(2017). Atypical antipsychotics for disruptive behaviour disorders in children and youths. Cochrane Database of Systematic Reviews, 8, CD008559.

42.

McKay

K. E.

Halperin

J. M.

(2006). ADHD, aggression, and antisocial behavior across the lifespan. Annals of the New York Academy of Sciences, 931(1), 84–96.

43.

Meltzer

H. Y.

Matsubara

Lee

J. C.

(1989). Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. Journal of Pharmacology and Experimental Therapeutics, 251(1), 238–246.

44.

MTA Cooperative Group. (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archives of General Psychiatry, 56(12), 1073–1086.

45.

Munetz

M. R.

Benjamin

(1988). How to examine patients using the Abnormal Involuntary Movement Scale. Hospital and Community Psychiatry, 39(11), 1172–1177.

46.

National Center for Health Statistics: National Center for Chronic Disease Prevention and Health Promotion. (2000a). 2 to 20 years: Boys body mass index-for-age percentiles. https://www.cdc.gov/growthcharts/data/set1clinical/cj41c023.pdf

47.

National Center for Health Statistics: National Center for Chronic Disease Prevention and Health Promotion. (2000b). 2 to 20 years: Girls body mass index-for-age percentiles. https://www.cdc.gov/growthcharts/data/set1clinical/cj41c024.pdf

48.

Olfson

King

Schoenbaum

(2015). Treatment of young people with antipsychotic medications in the United States. JAMA Psychiatry, 72(9), 867–874.

49.

Pappadopulos

Macintyre II

J. C.

Crismon

M. L.

Findling

R. L.

Malone

R. P.

Derivan

. . . Jensen

P. S.

(2003). Treatment Recommendations for the use of Antipsychotics for Aggressive Youth (TRAAY). Part II. Journal of the American Academy of Child & Adolescent Psychiatry, 42(2), 145–161.

50.

Pliszka

S. R.

Crismon

M. L.

Hughes

C. W.

Corners

C. K.

Emslie

G. J.

Jensen

P. S.

, . . . The Texas Consensus Conference Panel On Pharmacotherapy of Childhood Attention Deficit Hyperactivity Disorder. (2006). The Texas children’s medication algorithm project: Revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 45(6), 642–657.

51.

Posner

Brown

G. K.

Stanley

Brent

D. A.

Yershova

K. V.

Oquendo

M. A.

. . . Mann

J. J.

(2011). The Columbia-Suicide Severity Rating Scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults. American Journal of Psychiatry, 168(12), 1266–1277.

52.

Robb

A. S.

Schwabe

Ceresoli-Borroni

Nasser

Marcus

R. N.

. . . Findling

R. L.

(2019). A proposed anti-maladaptive aggression agent classification: Improving our approach to treating impulsive aggression. Postgraduate Medical, 131(2), 129–137.

53.

Saini

(2009). A meta-analysis of the psychological treatment of anger: Developing guidelines for evidence-based practice. Journal of the American Academy of Psychiatry and the Law, 37(4), 473–488.

54.

Saylor

K. E.

Amann

B. H.

(2016). Impulsive aggression as a comorbidity of attention-deficit/hyperactivity disorder in children and adolescents. Journal of Child and Adolescent Psychopharmacology, 26(1), 19–25.

55.

Scotto Rosato

Correll

C. U.

Pappadopulos

Chait

Crystal

Jensen

P. S.

, & Treatment of Maladaptive Aggressive in Youth Steering Committee. (2012). Treatment of maladaptive aggression in youth: CERT guidelines II. Treatments and ongoing management. Pediatrics, 129(6), e1577–e1586.

56.

Shelton

T. L.

Barkley

R. A.

Crosswait

Moorehouse

Fletcher

Barrett

. . . Metevia

(1998). Psychiatric and psychological morbidity as a function of adaptive disability in preschool children with aggressive and hyperactive-impulsive-inattentive behavior. Journal of Abnormal Child Psychology, 26(6), 475–494.

57.

Sikich

Frazier

J. A.

McClellan

Findling

R. L.

Vitiello

Ritz

. . . Lieberman

J. A.

(2008). Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: Findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. American Journal of Psychiatry, 165(11), 1420–1431.

58.

Simpson

G. M.

Angus

J. W.

(1970). A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica Suppl, 212, 11–19.

59.

Stawerska

Smyczynska

Hilczer

Lewinski

(2015). Does elevated morning prolactin concentration in children always mean the diagnosis of hyperprolactinemia? Experimental and Clinical Endocrinology & Diabetes, 123(7), 405–410.

60.

Stocks

J. D.

Taneja

B. K.

Baroldi

Findling

R. L.

(2012). A phase 2a randomized, parallel group, dose-ranging study of molindone in children with attention-deficit/hyperactivity disorder and persistent, serious conduct problems. Journal of Child and Adolescent Psychopharmacology, 22(2), 102–111.

61.

Swanson

J. M.

Sergeant

J. A.

Taylor

Sonuga-Barke

E. J. S.

Jensen

P. S.

Cantwell

D. P.

(1998). Attention-deficit hyperactivity disorder and hyperkinetic disorder. Lancet, 351(9100), 429–433.

62.

Sykes

D. A.

Moore

Stott

Holliday

Javitch

J. A.

Lane

J. R.

. . . Charlton

S. J.

(2017). Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors. Nature Communications, 8(1), 763.

63.

U.S. Food and Drug Administration. (2013). Determination that MOBAN (molindone hydrochloride) tablets (5 milligrams, 10 milligrams, 25 milligrams, 50 milligrams, and 100 milligrams) and capsules (5 milligrams, 10 milligrams, and 25 milligrams) were not withdrawn from sale for reasons of safety or effectiveness, 78. Federal Register, 66742. https://www.federalregister.gov/documents/2013/11/06/2013-26550/determination-that-moban-molindone-hydrochloride-tablets-5-milligrams-10-milligrams-25-milligrams-50

64.

Vitaro

Brendgen

Tremblay

R. E.

(2002). Reactively and proactively aggressive children: Antecedent and subsequent characteristics. Journal of Child Psychology and Psychiatry, 43(4), 495–505.

65.

Vitiello

Behar

Hunt

Stoff

Ricciuti

(1990). Subtyping aggression in children and adolescents. Journal of Neuropsychiatry and Clinical Neurosciences, 2(2), 189–192.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.60 MB